These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 12833654)

  • 41. Celltech acquisition sends mixed messages.
    Mitchell P
    Nat Biotechnol; 2004 Jul; 22(7):787. PubMed ID: 15229522
    [No Abstract]   [Full Text] [Related]  

  • 42. Technology evaluation: MLN-591, Cornell University/BZL Biologics/ImmunoGen/Millennium.
    Doehn C; Jocham D
    Curr Opin Mol Ther; 2002 Dec; 4(6):606-13. PubMed ID: 12596364
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pfizer-Pharmacia: the smart fit for the future.
    Wiggins WP
    Expert Opin Investig Drugs; 2003 Jan; 12(1):1-3. PubMed ID: 12517249
    [No Abstract]   [Full Text] [Related]  

  • 44. Drug evaluation: apilimod, an oral IL-12/IL-23 inhibitor for the treatment of autoimmune diseases and common variable immunodeficiency.
    Billich A
    IDrugs; 2007 Jan; 10(1):53-9. PubMed ID: 17187316
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Polyethylene glycols and their use in biology and medicine].
    Igudin LI; Markman GA; Loban' SA; Pozina IM; Migunov VN
    Zh Mikrobiol Epidemiol Immunobiol; 1984 Apr; (4):17-21. PubMed ID: 6377767
    [No Abstract]   [Full Text] [Related]  

  • 46. UK biotechnology. A public for Celltech?
    Newmark P
    Nature; 1983 Jul 21-27; 304(5923):202. PubMed ID: 6191224
    [No Abstract]   [Full Text] [Related]  

  • 47. Biotechnology: Celltech to change hands?
    Newark P
    Nature; 1989 Nov; 342(6248):334. PubMed ID: 2586596
    [No Abstract]   [Full Text] [Related]  

  • 48. PJect buys celltech vax.
    Nat Biotechnol; 2000 Oct; 18(10):1024. PubMed ID: 11017005
    [No Abstract]   [Full Text] [Related]  

  • 49. Intravenous CDP870, a PEGylated Fab' fragment of a humanized antitumour necrosis factor antibody, in patients with moderate-to-severe Crohn's disease: an exploratory study.
    Winter TA; Wright J; Ghosh S; Jahnsen J; Innes A; Round P
    Aliment Pharmacol Ther; 2004 Dec; 20(11-12):1337-46. PubMed ID: 15606396
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Certolizumab pegol: an evidence-based review of its place in the treatment of Crohn's disease.
    Cassinotti A; Ardizzone S; Porro GB
    Core Evid; 2008 Feb; 2(3):209-29. PubMed ID: 21221187
    [TBL] [Abstract][Full Text] [Related]  

  • 51. CDP-870. Celltech/Pfizer.
    Rose-John S; Schooltink H
    Curr Opin Investig Drugs; 2003 May; 4(5):588-92. PubMed ID: 12833654
    [TBL] [Abstract][Full Text] [Related]  

  • 52. CDP 571: anti-TNF monoclonal antibody, BAY 103356, BAY W 3356, Humicade.
    Drugs R D; 2003; 4(3):174-8. PubMed ID: 12757404
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Certolizumab pegol: a TNF-{alpha} antagonist for the treatment of moderate-to-severe Crohn's disease.
    Smith LS; Nelson M; Dolder CR
    Ann Pharmacother; 2010 Feb; 44(2):333-42. PubMed ID: 20118143
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Certolizumab pegol for the management of Crohn's disease in adults.
    Rivkin A
    Clin Ther; 2009 Jun; 31(6):1158-76. PubMed ID: 19695385
    [TBL] [Abstract][Full Text] [Related]  

  • 55. PEG-sTNF-RI. Amgen.
    Darlington C
    Curr Opin Investig Drugs; 2003 May; 4(5):583-7. PubMed ID: 12833653
    [TBL] [Abstract][Full Text] [Related]  

  • 56.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 57.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 58.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.